Review Article

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Table 1

Characteristics of the analysed trials.

StudyPhasePrimary endpointYears/RangeNumber of Patients Experimental ArmNumber of Placebo ArmsLine of treatmentExperimental arm

Li et al 2016IIIOS/PFS2011-201217691III/IV°Apatinib
TAGS 2018IIIOS2016-2018337170III/IV/V°°TAS-102
ATTRACTION-2 2017IIIOS2014-2016330163III/IV/V°°°Nivolumab

PFS: Progression free survival; OS: Overall survival.
III lines: 36% placebo; 34% apatinib
III lines: 62% placebo; 63% TAS-102
III lines: 82% placebo; 80% nivolumab